CEMI.US
id: 589
Chembio Diagnostics (CEMI) $8.1 MM Securities Settlement
E.D. New York
Court2:20-cv-02706
Case number03/12/2020
Class period Start06/16/2020
Class period End06/23/2023
Claim deadlineChembio Diagnostics (CEMI) paid $8.1 million to settle a securities class action lawsuit to avoid further litigation.
The Complaint alleged that the Company and its Leaders participated in a scheme to deceive the market by misrepresenting the effectiveness of the Company's DPP COVID-19 test. This conduct artificially inflated the price of Chembio stock and constituted fraud or deceit against purchasers of Chembio stock. When the truth about the negative factors affecting Chembio's business became public, the price of Chembio stock significantly dropped, resulting in a material decline that removed the inflation from the stock price. As a result, investors who purchased Chembio stock suffered real economic losses.
Case Status
Disbursement
Alleged Offence
Misleading Statements,
Failure to Disclose,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.65
Filing date
06/18/2020
Plaintiffs
Municipal Employees’ Retirement System of Michigan
Attorneys
Robbins Geller Rudman & Dowd LLP (Melville, NY), Rolnick Kramer Sadighi LLP (New York, NY)
Defendants
Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine I. Davis, Dr. Mary Lake Polan, Dr. John G. Potthoff
Judge
Hon. Allyne R. Ross
Administrator
Gilardi & Co LLC
Court hearing date
06/05/2023
Exclusion deadline
05/15/2023
Objection deadline
05/15/2023
Hearing deadline
05/15/2023
Trades matching type
FIFO
+$8,100,000
Cash Settlement Amount